CervoMed Inc. filings document a clinical-stage biotechnology issuer focused on neflamapimod and age-related brain disorders. Form 8-K reports include Regulation FD disclosures, press release exhibits, operating and financial results, and updates on clinical studies such as RewinD-LB in dementia with Lewy bodies, pharmacokinetic work, biomarker analyses, and ALS platform inclusion.
Proxy materials describe shareholder voting matters, board and governance practices, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also identifies CRVO common stock on the Nasdaq Capital Market and provides capital-structure, business-development, and financial-position disclosures relevant to CervoMed's drug-development model.
CervoMed Inc. director Marwan Sabbagh reported receiving a grant of stock options as part of his board compensation. On June 8, 2026, he was awarded options to purchase 8,150 shares of CervoMed common stock at an exercise price of $2.91 per share. These options were granted under the company’s 2025 Equity Incentive Plan in line with its non-employee director compensation policy. The options vest in substantially equal monthly installments over one year, with 1/12 of the underlying shares vesting on the last day of each month beginning June 30, 2026, contingent on his continued board service.
CervoMed Inc. director David Quigley received a stock option grant as part of his compensation for joining the board. On June 8, 2026, he was awarded options to buy 8,150 shares of CervoMed common stock at an exercise price of $2.91 per share, expiring on June 8, 2036.
The grant was made under the company’s 2025 Equity Incentive Plan and its non-employee director compensation policy. The underlying shares vest in substantially equal 1/12 monthly installments over one year, starting June 30, 2026, subject to his continued board service.
CervoMed Inc. reported that director Jeffrey V. Poulton received a stock option award tied to his election to the board. On June 8, 2026, he was granted options to purchase 8,150 shares of CervoMed common stock at an exercise price of $2.91 per share.
The award was granted under CervoMed’s 2025 Equity Incentive Plan pursuant to its non-employee director compensation policy. The underlying shares vest in substantially equal monthly installments over one year, with 1/12 of the award vesting on the last day of each month beginning on June 30, 2026, subject to his continued service.
CervoMed Inc. director Jane H. Hollingsworth received a stock option grant tied to her election to the board. The award covers 8,150 shares of CervoMed common stock with an exercise price of $2.91 per share and expires on June 8, 2036.
The option was granted under CervoMed’s 2025 Equity Incentive Plan in line with its non-employee director compensation policy. The underlying shares vest monthly over one year in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, contingent on continued board service.
CervoMed Inc. director and 10% owner Sylvie Gregoire received a stock option grant related to her election to the board. The award covers 8,150 shares of common stock at an exercise price of $2.91 per share and expires on June 8, 2036. The option was granted under CervoMed’s 2025 Equity Incentive Plan in line with its non-employee director compensation policy. The underlying shares will vest in 12 equal monthly installments on the last day of each month starting June 30, 2026, contingent on her continued board service.
CervoMed Inc. director and 10% owner Joshua S. Boger received a stock option grant in connection with his election to the board. The award covers 8,150 shares of common stock at an exercise price of $2.91 per share, expiring on June 8, 2036. These shares vest in substantially equal monthly installments over one year starting on June 30, 2026, conditioned on his continued board service.
CervoMed Inc. reported an insider equity award linked to its CEO and President, John J. Alam. The Form 4 shows a grant of stock options covering 8,150 shares of common stock at an exercise price of $2.91 per share, held indirectly through his spouse.
The options were granted to Dr. Sylvie Gregoire, a non-employee director and spouse of the reporting person. The filing states that Alam disclaims beneficial ownership of these securities. The underlying shares vest monthly over one year in substantially equal 1/12 increments, beginning on June 30, 2026, subject to Dr. Gregoire’s continued service.
CervoMed Inc. entered into a securities purchase agreement for a private placement of 3,360,377 units, each consisting of common stock or a pre-funded warrant plus Series B and Series C warrants, at $3.14 or $3.139 per unit, for anticipated gross proceeds of about $10.5 million.
The financing, which includes substantial participation from company insiders and institutional healthcare investors, could generate up to an additional $21.7 million if the Series B and Series C warrants are fully exercised for cash. CervoMed plans to use the funds to advance its lead drug neflamapimod and general corporate needs, and expects its cash runway, together with existing cash, to extend into the second quarter of 2027 while it pursues a strategic partnership to move neflamapimod into Phase 3 for dementia with Lewy bodies.
CervoMed Inc. held its 2026 Annual Meeting of Stockholders on June 8, 2026. Stockholders of record on April 17, 2026 could vote, with 9,258,719 shares of common stock outstanding as of that date.
Holders of 6,218,593 shares, or about 67.2% of shares outstanding, were present virtually or by proxy, so a quorum was achieved. All eight director nominees received the requisite plurality of votes and were elected. Three additional proposals, each requiring a majority of votes present and entitled to vote, were approved, including Proposal No. 2 with 6,092,751 votes for and Proposal No. 3 and Proposal No. 4 with more votes for than against.
CervoMed Inc. reported first-quarter 2026 results, including cash, cash equivalents and marketable securities of $12.9 million as of March 31, 2026. This compares to $20.9 million as of December 31, 2025, and the company expects this cash to fund operations into the third quarter of 2026.
For the quarter, CervoMed recorded no grant revenue versus approximately $1.9 million a year earlier, reflecting completion of its RewinD-LB trial and the end of related grant funding. Research and development expenses were about $5.1 million, up from $4.8 million, while general and administrative expenses rose to roughly $3.0 million from $2.4 million.
Net loss widened to approximately $8.0 million from $4.9 million, driven mainly by the grant revenue decline and higher operating costs. On the clinical side, the company highlighted extensive neflamapimod data in dementia with Lewy bodies and alignment with regulators on the final design of a planned Phase 3 trial, which it aims to start in the second half of 2026, subject to financing.